Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.
about
Prostate mechanical imaging: a new method for prostate assessmentCancer incidence in World Trade Center rescue and recovery workers, 2001-2008Interventions to encourage uptake of cancer screening for people with severe mental illnessScreening for prostate cancerInterventions to encourage uptake of cancer screening for people with severe mental illnessSurgical management of localised prostate cancerSurgical management of localised prostate cancerScreening for prostate cancerTwenty Years of PSA: From Prostate Antigen to Tumor MarkerMortality results from a randomized prostate-cancer screening trialScreening for prostate cancer: systematic review and meta-analysis of randomised controlled trialsOutcomes of localized prostate cancer following conservative managementProstate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005Overdiagnosis and breast cancer screeningDiagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic reviewCurrent status of active surveillance in prostate cancerOverdiagnosis and overtreatment of prostate cancerKallikreins as biomarkers for prostate cancerManagement of low (favourable)-risk prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening.Prostate cancer characteristics in the World Trade Center cohort, 2002-2013Emerging technologies for studying DNA methylation for the molecular diagnosis of cancerLong-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimatesRandomised prostate cancer screening trial: 20 year follow-upCalibration methods used in cancer simulation models and suggested reporting guidelinesMeanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment.Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants.Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering?Calibrating disease progression models using population data: a critical precursor to policy development in cancer controlUsing a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data.Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.Patterns of care and treatment trends for Canadian men with localized low-risk prostate cancer: an analysis of provincial cancer registry dataInsulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic diseaseAnalysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank.The overdiagnosis nightmare: a time for caution.Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancerIdentification of pathologically insignificant prostate cancer is not accurate in unscreened men.Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network
P2860
Q22162491-C5FDDA08-F4FE-4F62-8F82-5778D643189DQ23920944-84A0310B-DD2A-4074-A09F-0DC1E854C772Q24201183-297F6FE6-8E47-4F64-A8A1-C96245D2D53BQ24201690-DEDCE5FC-B076-45E9-B21B-D46518C7CC99Q24203756-9B8A0F36-79E7-4679-8AC7-2113857331C7Q24236194-843CB4E8-0224-4F88-A5AF-64DBD3A05662Q24240595-7D2525CA-6055-4E95-83AD-C9C5298710CFQ24245476-E970FCC3-F26C-4AB4-B0AE-4E6B46D6551DQ24564782-27E11A44-369D-44A8-8065-7BED77DE211DQ24601536-9AE313BB-F946-40F0-AD6C-3207183AD8DEQ24608493-56462DE6-9FE9-4F53-9429-B7F974334738Q24647380-7CFE895E-97F3-414F-92EC-3DEBC75FAA73Q24656098-BA06099A-0625-41F4-B966-76B96AD22C7DQ24813883-35F88238-42A6-40B9-99C2-362F299CAE1DQ26748872-D1352BDC-7CE6-499E-B6D3-84690F37FB5CQ26766307-17D36D48-D81E-411B-8C3C-E224467D0E73Q26859596-CA6FC54E-4850-4F05-8B1F-A27422EDA2E6Q26862434-9EAB2971-3B49-4198-9E45-E6C318CA3271Q26996501-F96894C3-AE93-4843-9EE7-2B920E6FE488Q27022847-F0A7C551-9710-4426-8A12-F6E6A637B0CBQ27314872-4D22FA9A-B8D9-4AC4-AABB-C0CE7761547FQ28065062-A87D8AE6-F466-4F8F-8451-05F6DB91A1E3Q28087759-E43CCCEE-4C54-48DB-83CB-B23D60E55536Q28251617-D50B00A6-891C-4D5A-889C-069D6422AE11Q28741447-5E77E3F2-5C75-48B1-92E0-BB0D0CE09924Q28749665-39A4AF0A-EFB9-44BC-995C-6109FAD57986Q30364894-18082B5C-C5A2-4AEF-BBD9-0FCE445C3007Q30453835-D27DFCD9-67EA-4672-B07E-9EC9442A4AF7Q30495334-E7D7315C-D998-4F37-B271-A8777755B68DQ30496883-727A8A00-C615-4ED1-9313-97329F03EA31Q30687378-85EB7660-F234-4569-9F98-34C4BA9DB3ECQ30878080-82A21C9A-C3AA-473D-989C-B9768D786236Q31056768-8F158FD5-46A5-4DB2-9210-9C11F1E20ECCQ33374241-93427715-D35F-4028-B25D-49DFCD97D219Q33449075-5511776D-D788-426C-9744-4C802A2EBD47Q33459386-2B4281C0-2559-4C95-AD87-E5C178B384B8Q33518914-D7B79329-8E42-42E2-8A46-566518BCA9C8Q33566716-F3CCBA77-A76D-4A45-AA2A-0F323ED53AEAQ33613656-6C6710E8-77D3-44DA-BF04-C62CDFD8BD06Q33677773-8CB071E6-5252-4A8C-B049-7C567B4017AB
P2860
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Lead times and overdetection d ...... Screening for Prostate Cancer.
@en
Lead times and overdetection d ...... Screening for Prostate Cancer.
@nl
type
label
Lead times and overdetection d ...... Screening for Prostate Cancer.
@en
Lead times and overdetection d ...... Screening for Prostate Cancer.
@nl
prefLabel
Lead times and overdetection d ...... Screening for Prostate Cancer.
@en
Lead times and overdetection d ...... Screening for Prostate Cancer.
@nl
P2093
P2860
P356
P1476
Lead times and overdetection d ...... Screening for Prostate Cancer
@en
P2093
Fritz H Schröder
Gerrit Draisma
Harry J de Koning
Ingrid W van der Cruijsen
Ronald A M Damhuis
Suzie J Otto
P2860
P304
P356
10.1093/JNCI/95.12.868
P407
P50
P577
2003-06-01T00:00:00Z